Exploring Protein Quantitation Methods to Detect Useful Plasma Biomarkers for Distinguishing Ischemic Stroke from Mimic (I2.013)

Conclusions: These results provide proof of concept that proteomic signals can be useful in ACVS diagnosis in more severe cases.The analyses have shaped our prospective verification (completed, n=560) and validation studies (ongoing, n=1200) of the use of proteomics in the diagnosis of mimic vs. mild-ACVS in early Emergency Department triage.Disclosure: Dr. Penn has received personal compensation for activities with Pfizer, Boehringer Ingelheim Pharmaceuticals, Inc., and Bayer as a speaker. Dr. Balshaw has nothing to disclose. Dr. Lesperance has nothing to disclose. Dr. Saly has nothing to disclose. Dr. Jackson has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Votova has received personal compensation for activities with Roche. Dr. Lu has nothing to disclose. Dr. Morrison has nothing to disclose. Dr. Coutts has nothing to disclose. Dr. Borchers has nothing to disclose.

Source: Neurology - April 3, 2016 Category: Neurology Authors: Penn, A., Balshaw, R., Lesperance, M., Saly, V., Jackson, A., Smith, D., Votova, K., Lu, L., Morrison, J., Coutts, S., Borchers, C. Tags: Stroke in the Elderly and Young: Challenges for the Next Decade Poster Presentations Source Type: research